ACRP Takes Toronto Star to Task
The Association of Clinical Research Professionals (ACRP) has responded to the editors of The Toronto Star in regard to its recent news and editorial coverage of Health Canada and the pharmaceutical industry in Canada.
The Association of Clinical Research Professionals (ACRP) has responded to the editors of The Toronto Star in regard to its recent news and editorial coverage of Health Canada and the pharmaceutical industry in Canada. The letter takes issue with the way the news coverage mischaracterizes and sensationalizes Health Canada's relationship with pharmaceutical companies. In addition, ACRP's Deputy Executive Director Terri Hinkley, maintains that its "inaccurate picture for the public that unnecessarily and irresponsibly cultivates distrust, discourages trial participation, and by default casts an underserved shadow on the thousands of dedicated professionals, fellow Canadians, who conduct clinical trials responsibly and ethically."
Soon after the article was published, other Canadian clinical trials experts aired their own opinions of the Star's portrayal.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
